News Roundup: Drug Makers Take Steps To Minimize Impact Of Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth, King update investors on generic Protonix, Skelaxin, while Ranbaxy wins tentative ANDA approval of Nexium generics.
You may also be interested in...
Teva Wins One, Loses One In Patent Challenge Appeals At The Federal Circuit
P&G's Actonel patent ruled valid: The U.S. Court of Appeals for the Federal Circuit rejected Teva's claims that the patent covering the active ingredient in Actonel (risedronate) was obvious and thus invalid. The court upheld a lower court decision that the unexpected results of the drug's potency and toxicity rebut Teva's claim that it was obvious to develop risedronate based on its similarity to another compound. P&G markets the osteoporosis drug in collaboration with Sanofi-Aventis. Actonel had more than $1 billion sales in 2008. The composition patent extends through June 2014 with the pediatric extension P&G received last month
Teva Wins One, Loses One In Patent Challenge Appeals At The Federal Circuit
P&G's Actonel patent ruled valid: The U.S. Court of Appeals for the Federal Circuit rejected Teva's claims that the patent covering the active ingredient in Actonel (risedronate) was obvious and thus invalid. The court upheld a lower court decision that the unexpected results of the drug's potency and toxicity rebut Teva's claim that it was obvious to develop risedronate based on its similarity to another compound. P&G markets the osteoporosis drug in collaboration with Sanofi-Aventis. Actonel had more than $1 billion sales in 2008. The composition patent extends through June 2014 with the pediatric extension P&G received last month
Musculoskeletal Pain Market Snapshot: Amrix is New Player in Field
Cephalon's novel musculoskeletal treatment Amrix appears positioned to give King's Skelaxin a run for the money. For King, however, a possible "at-risk" generic launch in 2009 presents a more immediate threat, analysts say